Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Numinus Wellness Inc NUMIF


Primary Symbol: T.NUMI

Healthcare
Numinus Wellness Inc. is a mental health care company. The Company focuses on advancing traditional and behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies. Its segments include Clinical research operations, Practitioner Training, Clinic network, and Corporate. Clinical research operations segment is focused on licensed psychedelic research and... see more

Recent & Breaking News (TSX:NUMI)

Numinus Applies for Management Cease Trade Order

PR Newswire 9 days ago

Numinus sells clinics to Stella, partners on mental health tech

Jocelyn Aspa 9 days ago

Numinus Wellness Announces Sale of Clinics and Unique Data Partnership to Increase Access to Mental Health Care

PR Newswire 9 days ago

Numinus Wellness Comments on FDA Decision on New Drug Application for MDMA-Assisted Therapy for PTSD

PR Newswire August 12, 2024

Numinus Wellness Inc. Announces Third Quarter Fiscal 2024 Results

PR Newswire July 11, 2024

Numinus to Host Q3 Fiscal 2024 Results Conference Call on July 11, 2024

PR Newswire July 10, 2024

Numinus Wellness Announces Resignation of Director

PR Newswire June 24, 2024

MedBright AI Announces Strategic Acquisition by Numinus Wellness

GlobeNewswire June 20, 2024

Numinus Wellness Announces Strategic Acquisition of MedBright AI

PR Newswire June 20, 2024

Numinus Clarifies Disclosures

Newsfile June 7, 2024

Numinus Wellness Comments on FDA Advisory Committee Meeting for Investigational MDMA-Assisted Therapy for PTSD

PR Newswire June 7, 2024

Numinus Wellness Announces Voting Results From its Annual General Meeting of Shareholders

PR Newswire May 31, 2024

Numinus Wellness Charts Path To Profitability While Strengthening Community Ties

Newsfile May 30, 2024

Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder

Newsfile May 30, 2024

Numinus approved for pioneering MDMA-based clinical trial

Trevor Abes  May 30, 2024

Numinus Wellness Receives Health Canada Approval for Study into Group Model for MDMA-Assisted Therapy

PR Newswire May 30, 2024

Numinus Wellness Focused on Boosting Profitability and Expanding Community Support

PR Newswire May 7, 2024

Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003

PR Newswire April 17, 2024

Numinus Wellness Provides Corporate Update

PR Newswire April 15, 2024

Numinus Wellness Inc. Announces Second Quarter Fiscal 2024 Results

PR Newswire April 12, 2024